How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic.
Hemasphere
; 4(4): e432, 2020 Aug.
Article
in English
| MEDLINE | ID: covidwho-1104995
ABSTRACT
Infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). These can be exacerbated by anti-leukemic treatments. In addition, the typical patients with CLL already have fragilities and background risk factors that apply to the general population for severe COVID-19. On these bases, patients with CLL may experience COVID-19 morbidity and mortality. Recurrent seasonal epidemics of SARS-CoV-2 are expected, and doctors taking care of patients with CLL must be prepared for the possibility of substantial resurgences of infection and adapt their approach to CLL management accordingly. In this Guideline Article, we aim at providing clinicians with a literature-informed expert opinion on the management of patients with CLL during SARS-CoV-2 epidemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Language:
English
Journal:
Hemasphere
Year:
2020
Document Type:
Article
Affiliation country:
Hs9.0000000000000432
Similar
MEDLINE
...
LILACS
LIS